GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives

Raffaele Borghini; Roberto Caronna; Giuseppe Donato; Antonio Picarelli

doi:10.1016/j.dld.2020.03.019

GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives

Dig Liver Dis. 2020 Jun;52(6):686-687. doi: 10.1016/j.dld.2020.03.019. Epub 2020 Apr 24.

Authors

Raffaele Borghini¹, Roberto Caronna², Giuseppe Donato³, Antonio Picarelli⁴

Affiliations

¹ Department of Translational and Precision Medicine, Sapienza University, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: raffaele.borghini@uniroma1.it.
² Department of Surgical Sciences, Sapienza University, Rome, Italy. Electronic address: roberto.caronna@uniroma1.it.
³ Department of Translational and Precision Medicine, Sapienza University, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: giuseppe.donato@uniroma1.it.
⁴ Department of Translational and Precision Medicine, Sapienza University, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: antonio.picarelli@uniroma1.it.

PMID: 32340888
DOI: 10.1016/j.dld.2020.03.019

No abstract available

Keywords: Anti-inflammatory treatment; Crohn's disease; Glucagon-like peptide (GLP) 2; Malabsorption; Parenteral nutrition; Short bowel syndrome (SBS); Teduglutide.

Publication types

Case Reports
Letter

MeSH terms

Anti-Inflammatory Agents / therapeutic use
Crohn Disease / drug therapy*
Female
Glucagon-Like Peptide 2 / therapeutic use*
Humans
Middle Aged
Peptides / therapeutic use*
Short Bowel Syndrome / drug therapy*
Treatment Outcome

Substances

Anti-Inflammatory Agents
Glucagon-Like Peptide 2
Peptides
teduglutide